Table 5. Theme 5 consensus... | American Society of Hematology

Table 5.

Theme 5 consensus recommendations

Defining allo-HSCT eligibility in the LATAM region	Strength of recommendation,∗ median score (mean score)	Level of consensus†
Q14. What are the key clinical criteria for identifying eligible candidates for allo-HSCT in the LATAM region? Consensus statement Evaluation for allo-HSCT is recommended for all patients with intermediate-2 or high-risk MF according to the DIPSS Plus‡ criteria; patient preferences and treatment goals should be considered during the decision-making process, alongside the specific capabilities of the treatment center. Key patient-related clinical criteria include: Age (<70 y) Patients >70 y may be considered for allo-HSCT according to the treatment center’s experience. Performance status CI Key disease-related clinical criteria include: Blast % High transfusion burden (even if low-risk MF) High-risk molecular or cytogenetic abnormalities For patients with intermediate-1 risk MF, identification of high-risk mutations using NGS-integrated risk stratification models will aid transplant decisions, where available.	9 (8.61)	n/N = 23/23 (100%)
Q15. How should JAKi treatment be managed before transplantation? Consensus statement JAKi treatment is recommended before transplantation for spleen and symptom control to improve transplant outcome. According to institutional transplant team policy, JAKi therapy may continue: Until initiation of pretransplant conditioning Until day 0 of transplantation After transplantation Abrupt dose reduction/discontinuation should always be avoided.	9 (8.72)	n/N = 25/25 (100%)

Defining allo-HSCT eligibility in the LATAM region

Strength of recommendation,∗
median score (mean score)

Level of consensus†

Q14. What are the key clinical criteria for identifying eligible candidates for allo-HSCT in the LATAM region?
Consensus statement
Evaluation for allo-HSCT is recommended for all patients with intermediate-2 or high-risk MF according to the DIPSS Plus‡ criteria; patient preferences and treatment goals should be considered during the decision-making process, alongside the specific capabilities of the treatment center.
Key patient-related clinical criteria include:

Age (<70 y)
- Patients >70 y may be considered for allo-HSCT according to the treatment center’s experience.
Performance status
CI

Key disease-related clinical criteria include:

Blast %
High transfusion burden (even if low-risk MF)
High-risk molecular or cytogenetic abnormalities

For patients with intermediate-1 risk MF, identification of high-risk mutations using NGS-integrated risk stratification models will aid transplant decisions, where available.

9 (8.61)

n/N = 23/23 (100%)

Q15. How should JAKi treatment be managed before transplantation?
Consensus statement
JAKi treatment is recommended before transplantation for spleen and symptom control to improve transplant outcome. According to institutional transplant team policy, JAKi therapy may continue:

Until initiation of pretransplant conditioning
Until day 0 of transplantation
After transplantation

Abrupt dose reduction/discontinuation should always be avoided.

9 (8.72)

n/N = 25/25 (100%)

∗

Median score on a 1 to 9 scale (mean score in parentheses).

†

Percentage of votes with 7 to 9 on a 9-point scale. Participants were provided with the voting option “Not Applicable” for recommendations outside their area expertise.

‡

Where DIPSS Plus is not available, other prognostic scores may be used (eg, DIPSS).

View Large

This Feature Is Available To Subscribers Only